COL2A1 - Neonatal Disorders

What is COL2A1?

The COL2A1 gene encodes the alpha-1 chain of type II collagen, a protein that forms cartilage and other connective tissues in the body. Mutations in this gene can lead to a variety of skeletal disorders and conditions, many of which present during childhood.

How does COL2A1 relate to skeletal disorders?

Mutations in the COL2A1 gene are responsible for several types of skeletal dysplasia, including Stickler syndrome, spondyloepiphyseal dysplasia (SED), and Kniest dysplasia. These conditions often manifest with a variety of symptoms such as short stature, joint problems, and distinctive facial features.

What are the symptoms of COL2A1-related disorders in children?

Children with COL2A1-related disorders may present with a range of symptoms including:

Myopia (nearsightedness)
Hearing loss
Cleft palate
Joint pain and stiffness
Short stature
Spinal abnormalities

How are COL2A1 mutations diagnosed?

Diagnosis often involves a combination of clinical examination, imaging studies like X-rays or MRIs, and genetic testing to identify mutations in the COL2A1 gene. Early diagnosis can help in managing symptoms and planning appropriate treatments.

What treatment options are available?

While there is no cure for disorders caused by COL2A1 mutations, several treatment options can help manage symptoms:

Physical therapy to improve mobility and reduce joint pain
Surgical interventions for severe skeletal abnormalities
Hearing aids for hearing loss
Glasses or contact lenses for vision problems

Early intervention and a multidisciplinary approach are often crucial in improving the quality of life for affected children.

What is the prognosis for children with COL2A1-related disorders?

The prognosis varies depending on the specific disorder and its severity. With appropriate medical care, many children can lead relatively normal lives, although they may require ongoing management of their symptoms.

Are there any ongoing research or advancements?

Research is ongoing to better understand the mechanisms of COL2A1 mutations and to develop targeted therapies. Advances in gene therapy and regenerative medicine hold promise for future treatments that could potentially correct the underlying genetic defects.

Relevant Publications

Construction of mitochondrial-targeting nano-prodrug for enhanced Rhein delivery and treatment for osteoarthritis in vitro.

Issue Release: 2024

Inhibition of caspase-11 under inflammatory conditions suppresses chondrogenic differentiation.

Issue Release: 2024

Pre-hypertrophic chondrogenic enhancer landscape of limb and axial skeleton development.

Issue Release: 2024

Cyclic negative pressure promotes chondrocyte growth: Association of IGF-2 with EGR-1.

Issue Release: 2024

PPARγ regulates osteoarthritis chondrocytes apoptosis through caspase-3 dependent mitochondrial pathway.

Issue Release: 2024

The role of semaphorin 3A on chondrogenic differentiation.

Issue Release: 2024

Activation of Notch Signaling Pathway is involved in Extracellular Matrix Degradation in Human Induced Pluripotent Stem Cells Chondrocytes Induced by HT-2 Toxin.

Issue Release: 2024

Collagen and Alginate Hydrogels Support Chondrocytes Redifferentiation In Vitro without Supplementation of Exogenous Growth Factors.

Issue Release: 2024

The c-Fos/AP-1 inhibitor inhibits sulfur mustard-induced chondrogenesis impairment in zebrafish larvae.

Issue Release: 2024

Excessive mechanical loading promotes osteoarthritis development by upregulating Rcn2.

Issue Release: 2024

Exosomes from umbilical cord mesenchymal stem cells ameliorate intervertebral disc degeneration via repairing mitochondrial dysfunction.

Issue Release: 2024

[ Capsule alleviates interleukin-1β-induced chondrocyte inflammation and extracellular matrix degradation by regulating the miR-502-5p/TRAF2/NF-κB axis].

Issue Release: 2024

Network Pharmacology and Experimental Validation to Elucidate the Pharmacological Mechanisms of Luteolin Against Chondrocyte Senescence.

Issue Release: 2024

XJB-5-131 protects chondrocytes from ferroptosis to alleviate osteoarthritis progression via restoring Pebp1 expression.

Issue Release: 2024

Long Non-coding RNA DLEU1 Promotes Progression of Osteoarthritis via miR-492/TLR8 Axis.

Issue Release: 2024

System biology approaches to identify hub genes linked with ECM organization and inflammatory signaling pathways in schizophrenia pathogenesis.

Issue Release: 2024

Screening Mutations of the Monogenic Syndromic High Myopia by Whole Exome Sequencing From MAGIC Project.

Issue Release: 2024

Robotics-Driven Manufacturing of Cartilaginous Microtissues for Skeletal Tissue Engineering Applications.

Issue Release: 2024

Involvement of Yes-Associated Protein 1 Activation in the Matrix Degradation of Human-Induced-Pluripotent-Stem-Cell-Derived Chondrocytes Induced by T-2 Toxin and Deoxynivalenol Alone and in Combination.

Issue Release: 2024

Molecular mechanism of miR-203a targeting Runx2 to regulate thiram induced-chondrocyte development.

Issue Release: 2024

Can Sensorimotor Disorders be Prevented?

What is Optic Atrophy?

What is a Multidisciplinary Team?

What Are the Key Focus Areas of VON?

How Can Cultural Factors Influence Pediatric Care?

What are the Challenges Faced by Pediatric Nurses in Neonatal Care?

What are Primary Teeth?

How Does Digital Advertising Affect Children?

What Does a Typical Session Look Like?

How Does Education Play a Role?

Partnered Content Networks

Relevant Topics